BioSpace News Archive

The American Society of Cannabis Medicine announced that members of its leadership have been asked to participate at the Second Annual Update on Medical Cannabis Friday, Sept. 27 presented by the Department of Psychiatry and Behavioral Sciences of the Medical University of South Carolina.

Acacia Diversified Holdings, Inc., www.acaciadiversifiedholdings.com an emerging cannabis company, is announcing its receipt of its second food grade manufactures permit in the company’s mobile fleet.

Growing Body of Evidence Supporting Use of the Tack Endovascular System® to Improve Balloon Angioplasty Outcomes for Patients Suffering from PAD

Sunovion Pharmaceuticals Inc. and PsychoGenics Inc. announced the initiation of the DIAMOND (Developing Innovative Approaches for Mental Disorders) Phase 3 studies for SEP-363856, a novel agent for the treatment of adults and adolescents with schizophrenia.

Xstrahl Medical, global leader in superficial radiotherapy devices to treat non-melanoma skin cancer and dermatological conditions, is featuring its RADiant treatment system at the Fall Texas Dermatology meeting in San Antonio, Texas, from September 27th-29th.

The global asthma spacers market size is poised to grow by USD 297.72 million during 2019-2023, according to a new report by Technavio, progressing at a CAGR of over 4% during the forecast period.

22NW, LP is one of the largest shareholders of Catalyst Biosciences, Inc with ownership of approximately 6% of the Company’s outstanding shares.

TraceLink Inc. announced the industry-leading speakers for FutureLink Nashville, including pharmaceutical CIOs, hospital supply chain leaders, serialization experts and leading industry analysts.

Context-Aware Packaging Is Just the Tip of the Iceberg Says Third Aurora

Incyte (Nasdaq:INCY) announces updated results, including the final result for the primary endpoint, from its Phase 2 FIGHT-202 trial evaluating pemigatinib, a selective fibroblast growth factor receptor (FGFR) inhibitor, as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma.